Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Profit or Loss and Significant Segment Expenses

Additional information about segment profit or loss and significant segment expenses is as follows:

	Three Months Ended March 31,
	2025		2024
Direct R&D program expense
BHV-4157 (Troriluzole)	$	13,788	$	17,087
BHV-2000 (Taldefgrobep Alfa)	6,184		11,128
BHV-7000 & BHV-7010 (Kv7)	31,573		24,803
BHV-2100 (TRPM3 Antagonist)	16,748		4,620
BHV-8000 (TYK2/JAK1)	4,373		4,249
BHV-1300 (IgG Degrader)	8,621		9,225
BHV-1310 (IgG Degrader)	1,074		3,261
BHV-1400 (IgA Degrader)	4,860		4,092
BHV-1600 (β1-AR AAB Degrader)	3,003		815
BHV-1510 (Trop2)	4,490		19,586
BHV-1530 (FGFR3)	3,176		—
Other R&D program expense	511		(241)
Preclinical research programs R&D Expense	25,535		11,863
R&D personnel expense (excluding share-based compensation)(1)	21,138		19,314
R&D Share-based compensation expense	35,233		21,291
G&A personnel expense (excluding share-based compensation)(1)	6,474		6,389
G&A Share-based compensation expense	17,829		13,586
Other segment items (2)	16,951		12,172
Non-operating (income) expense	(493)		(4,305)
Provision for income taxes	609		569
Segment net loss	221,677		179,504
Reconciliation of profit or loss
Adjustments and reconciling items	—		—
Consolidated net loss	$	221,677	$	179,504

(1)    Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other.

(2)    Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.